J.P. Morgan Notebook: Wednesday, January 15
This article was originally published in The Pink Sheet Daily
We bring you news and notes from the third day of the 2014 J.P. Morgan Healthcare conference, which includes highlights from Genentech, Teva, Sarepta, and new accelerator StartUp Health.
You may also be interested in...
A day after announcing the abrupt resignation of CEO Jeremy Levin, Teva’s management emphasized that the company’s current strategy would continue, including plans for dealing with ongoing pressures from Copaxone’s loss of exclusivity, and under-performance of the European generics businesses. Teva hoped to persuade rattled investors of its steady road to growth.
As traditional venture-like returns are harder to generate from drug development and medtech plays, some frustrated VCs see new opportunities in health care information technology, an area many have traditionally avoided.
The AIM-listed tech transfer group Imperial Innovations has raised £140 million to increase its early-stage investments in spin-outs from Imperial College and three other top UK universities